Europe Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this squeeze but thriving in it – through diversification, geographic focus, R&D intensity, or sheer scientific specialisation. Here’s how four of…

Europe The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for AbbVie, BeOne Medicines, CSL, Merz Therapeutics, and Novartis would love to see this realised and agree that Europe’s scientific fundamentals…

UK Seven months into the job as CEO of GSK, Luke Miels has moved faster and bigger than most expected. Having laid out an M&A strategy based around small bolt-ons at the start of the year, Miels then ripped up his own rule book with the USD 10.6 billion acquisition of…

Europe Strong patent portfolios can create substantial commercial value for biopharma companies. As Isobel Barry, partner at life sciences-focused IP firm Carpmaels & Ransford LLP explains,  opportunities to patent new small molecule, biologics and complex therapeutics arise throughout the go-to-market process, from early-stage research, through formulation development and clinical trials, up…

Europe The EU Health Technology Assessment Regulation was implemented in January 2025 to replace 27 fragmented national evaluations with a single Joint Clinical Assessment, run in parallel with EMA review. The idea was simple enough and aimed at giving European patients faster, more equitable access to innovative medicines. In practice, the…

Germany Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute for Drugs and Medical Devices (BfArM) outline how the Act attempts to revitalise clinical research in Germany, balancing faster procedures…

Global Sally Epstein looks at why the world’s biggest AI companies are all pivoting towards biopharmaceuticals. Epstein, an entrepreneur in residence at Cambridge Innovation Capital, argues that drug discovery – if done right – could be where the AI industry has the biggest societal impact (and can therefore justify companies’ enormous…

Global Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted action. Ahead of the G7 Leaders’ Summit in Evian on 15-17 June 2026, David Reddy, Director General of IFPMA, stresses…

Europe A 2025 collection of perspectives from over 30 biopharmaceutical industry stakeholders finds that while patient centricity has made real progress — moving from an afterthought to an expectation in the US and Europe — implementation remains patchy and often superficial. As Matthew Reaney, writing in ISPOR’s Value & Outcomes Spotlight…

Germany New legislation is putting Germany’s status as Europe’s most innovation-friendly pharma market under severe threat.   Germany has long led Europe in terms of both the number of new medicines available and the speed with which they are launched. German patients were able to enjoy a full 93 percent of…

Global Jay Iyer, CEO of the Access to Medicine Foundation, warns that rising nationalism and “onshoring” risk dismantling decades of progress in global health. As geopolitical tensions reshape how drugs are made and priced, Iyer argues that fragmented supply chains and profit-driven R&D often leave low-income nations – and the world’s…

Europe The European Health Data Space (EHDS) is a landmark regulation designed to unify health data across the EU for both direct patient care and medical research. Writing in the April 2026 edition of DIA’s Global Forum magazine, Tom Brookland, Pascal Hofer, and Didier Pomeranc of Roche explain that while the…